Development of a xylazine constant rate infusion with or without butorphanol for standing sedation of horses.

This research article presents the development and study of protocols for continuous-rate infusion of the sedative xylazine, either alone or in combination with butorphanol, to manage sedation in horses. The study found that xylazine alone was effective in maintaining steady sedation and blood plasma concentrations, but the additional use of butorphanol increased the risk of ataxia and seemingly early wakefulness, without reducing the need for xylazine.

Research Methodology

• The study was a blinded randomized experimental study involving ten adult research horses. The primary marker used to gauge the depth of sedation was the horse’s Height of Head Above Ground (HHAG).
• Part I of the study involved administering a loading dose of xylazine along with either butorphanol or saline, followed by a continuous rate infusion (CRI) of either butorphanol or saline, for 2 hours. Additional boluses of xylazine were given whenever HHAG exceeded 50%. The dosage of xylazine necessary to maintain sedation was calculated for both groups.
• In Part II, the previously calculated xylazine infusion rates were administered along with either butorphanol or saline, and the level of sedation was evaluated. Blood plasma concentrations of xylazine were also measured at various time points.
• The obtained data were thoroughly analyzed using statistical techniques including paired t-test, Wilcoxon signed-rank test and 2-way ANOVA for repeated measures.

Key Findings

• There were no significant differences noted in the xylazine dosage requirements between the group that received xylazine and butorphanol (XB), and the group that received xylazine and saline (X).
• The xylazine-only treatment led to lasting sedation in the horses. However, the combined use of xylazine and butorphanol resulted in five instances of horses falling down, and four cases where horses appeared insufficiently sedated.
• Measurements of blood plasma concentrations indicated that levels of xylazine in the bloodstream remained steady 45 minutes into the infusion, in both treatment groups.

Conclusions and Implications

• The research concluded that xylazine given as a loading dose followed by CRI can produce steady, lasting sedation in horses.
• The additional use of butorphanol did not reduce the amount of xylazine required, and instead increased instances of ataxia (loss of control of body movements) and apparently premature awakenings.
• The authors noted that these findings should be approached with caution when extrapolating to clinical conditions, as their study was conducted on healthy, unstimulated horses.